Investigating new treatments for rare skin lymphomas
A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...
Armed robbery in Revesby2 小时
Canada, Ontario Ink Rare Disease Drug Deal
Health CanadaIn Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment ...
Verywell Health on MSN1 年
How to Recognize Skin Lymphoma Symptoms
Medically reviewed by Gagandeep Brar, MD Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually ...
Pharmaceutical Technology18 天
CTX-131 by CRISPR Therapeutics for T-Cell Lymphomas: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...
Pharmaceutical Technology24 天
Durvalumab by AstraZeneca for Neuroendocrine Carcinoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.
Medscape14 天
Vorinostat: A Novel Therapy for the Treatment of Cutaneous T-cell Lymphoma
The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL ...
Nasdaq1 个月
Innate Pharma announces new data from TELLOMAK study
Innate Pharma (IPHA) announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma ... particularly Sezary syndrome and mycosis fungoides ...